Forget Eli Lilly and Company: as June Volatility Rocks High-flyers, This Stock is a No-brainer Buy
Quick Read - Pfizer trades at 9x forward earnings, pays a 6.6% dividend backed by real free cash flow, and eleven directors simultaneously bought shares in April. - Eli Lilly's entire growth story rides two drugs while investors pay 41x trailing earnings, with realized prices...<